Glomerular disease
Europe revoked avacopan after regulators called its pivotal trial's data unreliable. What now for patients doing well on it?
Europe revoked avacopan on August 4, after regulators called the ADVOCATE trial's efficacy data unreliable and weighed its liver-injury signal against it. The FDA alleges the one-year result was re-scored after unblinding; Amgen disputes it. A taskforce argues to keep access for a few.